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ABSTRACT
Background: Angiopoietin-like protein 4 (ANGPTL4)
inhibits lipoprotein lipase and associates with
dyslipidemia. The expression of ANGPTL4 is regulated
by free fatty acids (FFA) that activate lipid-sensing
peroxisome proliferator-activated receptors (PPARs),
but FFA can also activate pattern recognition receptors
including Toll-like receptor 4 (TLR4) in macrophages.
Objective: To assess whether systemic low-grade
inflammation is a determinant for plasma ANGPTL4
levels in patients with the metabolic syndrome (MetS)
and type 2 diabetes mellitus (T2DM).
Design: We studied 335 male participants: healthy
controls (Controls), patients with the MetS without
inflammation (MetS−I) and with low-grade
inflammation (MetS+I), and patients with T2DM. All
patients without diabetes included in the present study
were initially matched for waist circumference. In
plasma, ANGPTL4, C reactive protein (CRP) and
metabolic parameters were determined. Underlying
mechanisms were examined using human
macrophages in vitro.
Results: As compared with Controls, plasma
ANGPTL4 levels were increased in patients with
MetS−I, MetS+I, and T2DM. Furthermore, ANGPTL4
was increased in T2DM compared with MetS−I.
In fact, plasma CRP correlated positively with plasma
ANGPTL4. In vitro studies showed that TLR 3/4
activation largely increased the expression and release
of ANGPTL4 by macrophages.
Conclusions: Plasma ANGPTL4 levels in humans are
predicted by CRP, a marker of inflammation, and
ANGPTL4 expression by macrophages is increased by
inflammatory stimuli.
INTRODUCTION
The angiopoietin-like proteins are a family of
secreted proteins that play an important role
in energy metabolism. Angiopoietin-like
protein 4 (ANGPTL4) is expressed in numer-
ous cell types including adipocytes, hepato-
cytes, (cardio)myocytes, endothelial cells,
and macrophages.1 2 ANGPTL4 plays a role
in plasma lipid metabolism by inhibiting the
enzyme lipoprotein lipase. This action of
ANGPTL4 results in suppression of the
release of plasma TG-derived fatty acids and
their subsequent uptake by underlying meta-
bolic tissues including adipose tissue, skeletal
muscle, and the heart, with concomitant
hypertriglyceridemia.3–5
Expression of ANGPTL4 in a variety of
tissues, including adipose tissue and liver, is
governed by the lipid-sensing peroxisome
proliferator-activated receptors (PPARs) α, β,
and γ, and is stimulated in vitro by free fatty
acids (FFA).1 6–8 Accordingly, dietary modu-
lations that increase plasma FFA levels,
including prolonged fasting, very-low-calorie
diet, and high-fat, high-energy diet, also
increase plasma ANGPTL4 levels, most likely
via activation of PPARs in tissues such as
adipose tissue and liver.9 10 Besides activating
PPARs, there is compelling evidence that FFA
also activate pattern recognition receptors
(PRRs) in adipocytes and macrophages,
including the Toll-like receptor 4 (TLR4).11 12
Accordingly, it is of interest to study the
impact of inﬂammation and (associated) TLR
activation on ANGPTL4 expression.
The metabolic syndrome (MetS) is a pro-
gressive inﬂammatory disease, ranging from
mild dyslipidemia and impaired fasting
glucose levels to full blown type 2 diabetes
Key messages
▪ Plasma angiopoietin-like protein 4 (ANGPTL4)
levels in humans are predicted by the inflamma-
tory marker C reactive protein (CRP).
▪ Inflammatory stimuli increase ANGPTL4 expres-
sion by macrophages in vitro.
▪ Therefore a novel link is provided between
inflammation and ANGPTL4 expression.
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mellitus (T2DM).13 14 Interestingly, the progression of
MetS towards T2DM is accompanied by progressive
inﬂammation, which may result in increased plasma
levels of ANGPTL4 that, in turn, could aggravate dyslipi-
demia. Therefore, the aim of the present study was to
assess whether systemic low-grade inﬂammation is a
determinant for plasma ANGPTL4 levels in patients with
the MetS and T2DM. To get more insight into the
causal relationship between inﬂammation and
ANGPTL4 expression we assessed whether inﬂammatory
stimuli increase ANGPTL4 expression in vitro.
RESEARCH DESIGN AND METHODS
Human studies
Subjects
To assess the effects of low-grade systemic inﬂammation
on plasma ANGPTL4 levels we studied four groups of
human participants: healthy controls (Controls, n=95),
patients with MetS but without systemic inﬂammation
(MetS−I, n=106), patients with MetS accompanied by
low-grade systemic inﬂammation (MetS+I, n=66), and
patients with T2DM (n=68). All patients without diabetes
included in the present study were initially matched for
waist circumference (maximum difference 17 cm) and age
(maximum difference 19 years). The MetS was deﬁned
according to the International Diabetes Federation (IDF) cri-
teria,15 that is, two or more of the following criteria present
in addition to increased waist circumference (male ≥94):
triglycerides ≥1.7 mmol/L (≥150 mg/dL)/the use of
lipid-lowering medication, high-density lipoprotein (HDL)
cholesterol <1.03 mmol/L (<40 mg/dL) in men and
<1.29 mmol/L (<50 mg/dL) in women, fasting glucose
≥5.6 mmol/L (100 mg/dL) or blood pressure (BP)
≥130/≥85 mmHg/the use of BP-lowering medication.
Low-grade inﬂammation was deﬁned as moderately ele-
vated C reactive protein (CRP): 3 mg/L≤CRP <15 mg/L.
Controls (n=95), patients with MetS−I (n=66; 62% of
all included patients with MetS−I) and patients with
MetS+I (n=33; 50% of all included patients with MetS+I)
were selected from a survey in the general population in
the city of Rijswijk, the Netherlands. For this survey, all
patients without diabetes between 40 and 70 years of age
of four general practitioners were invited for a cardiovas-
cular risk screening (n=2942). Patients with diagnosed
diabetes, known terminal disease, and a history of psy-
chiatric disorders or substance abuse were excluded.
Screening was performed on 2079 patients (response
rate of 71%) and CRP was determined for 1515 patients.
After excluding patients with high CRP (deﬁned as
>15 mg/L, n=45), patients with missing values (n=13),
female patients (n=792) and patients with cardiovascular
disease (n=55), and 610 male patients were eligible.
Only male patients were selected to avoid the potential
interference of sex steroid hormones on study para-
meters. The MetS was present in 44% (n=268) of the
610 male patients. A total of 98 Controls and 102
patients with MetS were selected for the current study.
In addition 1 patient with new diagnosed diabetes,
1 patient with a very high level of ANGPTL4 and
4 patients with missing data (n=3 Control and n=1
MetS) were excluded therefore leading to 95 Controls
and 99 patients with MetS. Patients with MetS were
divided into MetS−I (n=66) and MetS+I (n=33).
Patients with MetS−I (n=40) and MetS+I (n=33) were
also selected from a previously published study on the
effect of lifestyle in combination with rosiglitazone
versus placebo on atherosclerosis in patients with MetS
(RUBENS study16). These patients (n=73) were matched
on waist and age with the patients from the PIRAMID
study (see below). For this study male patients with
increased waist circumference (≥94 cm) and elevated
CRP levels (≥1.8 mg/L) and two other MetS criteria
were included. Exclusion criteria for this study were
T2DM (fasting blood glucose ≥7 mmol/L), manifest car-
diovascular disease, use of statins, steroids or non-
steroidal anti-inﬂammatory drugs at baseline, heart
failure, QTc time interval of 450 ms or longer on base-
line ECG, primary dyslipidemias, presence of potential
hepatic disease (ie, patients with alanine aminotransfer-
ase, total bilirubin,or alkaline phosphatase levels exceed-
ing 2.5 times the upper limit of the normal laboratory
values), alcohol abuse (>30 units/week) and cardiovas-
cular MR contraindications.
Patients with T2DM (n=68) were selected from a
recently published study on the effects of pioglitazone
versus placebo on cardiovascular parameters in uncom-
plicated T2DM (PIRAMID) study. For detailed inclusion
criteria, see ref. 17. In short, the study included male
patients with T2DM without cardiovascular disease or
diabetes-related complications, body mass index (BMI)
25–32 kg/m2, age 45–65 years, and well-controlled
T2DM with oral antidiabetic medication (glycated
hemoglobin (HbA1c) 6.5–8.5%). A total of 73 patients
from the PIRAMID were matched on waist circumfer-
ence and age with 73 patients from the RUBENS.
A total of ﬁve patients were excluded due to CRP levels
>15 (n=4) and missing data (n=1).
The studies were executed in accordance with the
principles of the Declaration of Helsinki and were
approved by the local medical ethics committee. All
volunteers in these studies signed an informed consent.
Analysis of CRP and ANGPTL4
CRP was determined by the Tina Quant C reactive
protein (latex) high-sensitive assay according to the man-
ufacturer’s instructions (Roche, Basel, Switzerland).
ANGPTL4 was measured by ELISA as detailed previ-
ously.9 Brieﬂy, 96-well plates were coated with antihuman
ANGPTL4 polyclonal goat IgG antibody (AF3485, R&D
Systems) and incubated overnight at 4°C. Plates were
washed extensively between each step. After blocking,
100 µL of undiluted medium or 20-fold diluted human
plasma was added, followed by 2 h incubation at room
temperature. A standard curve was prepared using
recombinant human ANGPTL4 (3485-AN, R&D
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Systems) at 0.3–2.1 ng/well. Next, 100 µL of diluted bio-
tinylated antihuman ANGPTL4 polyclonal goat IgG anti-
body (BAF3485, R&D Systems) was added for 2 h,
followed by addition of streptavidin-conjugated horserad-
ish peroxidase for 20 min, and tetramethyl benzidine
substrate reagent for 6 min. The reaction was stopped by
addition of 50 µL of 10% H2SO4, and the absorbance
was measured at 450 nm.
In vitro studies
Cell culture
Human THP-1 and U937 monocytes were grown in
RPMI medium containing 10% heat-inactivated fetal calf
serum (FCS) and 1% P/S for 10–15 passages. They were
differentiated into macrophages after 2 days of incubation
by adding 100 ng/mL phorbol-12-myristate-13-acetate
(PMA). After 2 days, PMA was removed by washing with
phosphate-buffered saline and macrophages were kept in
complete medium without PMA for two additional days
and then used for experiments. Human peripheral blood
mononuclear cells (PBMCs) were isolated from whole
blood by using BD Vacutainer Cell Preparation Tubes
according to the manufacturer’s instructions. Isolated
PBMCs were plated in complete medium RPMI, 10%
heat-inactivated FCS, 1% P/S. After 2 h cells were
washed and remaining attached cells were differentiated
into macrophages in completed medium, containing
100 ng/mL macrophage colony stimulating factor, for ﬁve
subsequent days. During differentiation medium was not
refreshed.
Incubations
THP-1 cells were incubated with the TLR agonists
(Sigma, Fluka, Brunwich, and InvivoGen) lipopolysac-
charide (LPS, TLR4; 100 ng/mL or 1 µg/mL),
S-(2,3-bispalmitoyloxypropyl)-Cys-Gly-Asp-Pro-Lys-His-Pro--
Lys-Ser-Phe, Pam2CGDPKHPKSF (ﬁbroblast-stimulating
lipopeptide; FSL-1, TLR2, and TLR6; 1 μg/mL),
tri-acylated lipopeptide Pam3-Cys-Ser-Lys4 (Pam3, TLR1
and TLR2; 1 μg/mL), polyinosinic-polycytidylic acid (poly
(I:C), TLR3; 2 μg/mL), muramyl dipeptide (MDP, NOD2;
10 μg/mL), ﬂagellin (Flag, TLR5; 10 ng/mL) and/or
FFA-donor intralipid (2 mM; Fresenius Kabi) for the indi-
cated time periods at 37°C. After incubation, medium was
aspired and cells were washed. Cellular ANGPTL4 mRNA
was determined by qPCR (forward primer CACAGCCT
GCAGACACAACTC; reverse primer GGAGGCCAAACT
GGCTTTGC) and ANGPTL4 protein in the medium was
determined by ELISA as detailed above.
Statistical analysis
Data are expressed as mean±SD or as median (IQR) if
the assumption of normality was not met. Categorical
data are presented as frequencies (%). Comparisons
between continuous variables were assessed by inde-
pendent t test or one-way analysis of variance (ANOVA),
followed by Bonferroni’s post hoc test for multiple com-
parisons (table 1 and ﬁgure 1). Comparisons between
categorical data were performed with χ2 tests (with the
level of signiﬁcance adjusted for the number of compari-
sons, table 1). The correlation between clinical
characteristics and ANGPTL4 was tested by Spearman’s
correlation coefﬁcients (ﬁgure 2) and multivariable
regression analysis with logarithmically transformed
ANGPTL4 values. Statistical analysis was performed
using SPSS for Windows (V.17.0; SPSS, Chicago, Illinois,
USA). Plots were created with GraphPad Prism V.5.0
(GraphPad Software, Inc, La Jolla, California, USA).
p Value <0.05 was considered statistically signiﬁcant.
RESULTS
Characteristics of the human study population
To evaluate whether low-grade inﬂammation is asso-
ciated with plasma ANGPTL4 levels in humans, we com-
pared Controls (n=95) with patients with MetS−I
(n=106), MetS+I (n=66) and T2DM (n=68).
The mean age of all male patients combined (n=335)
was 56.9±6.0 years and mean waist circumference was 105
±10 cm. Clinical characteristics of the study population
are described in table 1. Groups matched for age and
waist circumference did not differ with regard to FFA and
family history of cardiovascular disease. Fasting glucose
and triglyceride levels were higher, and HDL-cholesterol
levels were lower in MetS−I, MetS+I and T2DM com-
pared with Controls. BP was higher in MetS−I and MetS
+I compared with Controls and T2DM. Patients with
T2DM used more statins and had lower total cholesterol
compared with MetS−I, MetS+I and Controls.
Furthermore patients with MetS+I smoked more fre-
quently then Controls and patients with T2DM.
Low-grade inﬂammation measured as CRP was highest in
MetS+I (5.55 (4.11–8.02) mg/L, p<0.001 compared with
all groups), followed by T2DM (3.60 (2.43–5.95) mg/L),
MetS−I (1.96 (0.92–2.37) mg/L) and Controls (1.43
(0.76–2.85) mg/L).
Plasma ANGPTL4 levels
The median plasma ANGPTL4 in the total study popula-
tion was 5.00 (3.50–6.80) ng/mL and ranged from 0.90
to 43.30 ng/mL. The distribution of ANGPTL4 was
skewed to the right. Figure 1 shows the plasma ANGPTL4
levels in Controls, MetS−I, MetS+I and T2DM. Plasma
ANGPTL4 was higher in T2DM (6.4 (5.2–8.2) ng/mL,
p<0.001), in MetS+I (6.0 (3.8–7.7) ng/mL, p<0.001) and
MetS−I (4.6 (3.3–6.5) ng/mL, p=0.006), than in Controls
(3.7 (2.8–5.2) ng/mL). In addition, higher ANGPTL4
was found in T2DM compared with MetS−I (p<0.001;
table 1).
Relationship between plasma ANGPTL4, metabolic
parameters and low-grade inflammation
Although groups were matched for waist circumference,
in all patients combined plasma ANGPTL4 positively
correlated with waist circumference (r=0.195, p<0.001)
and fasting glucose (r=0.322, p<0.001). Plasma
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ANGPTL4 negatively correlated with HDL-cholesterol
(r=−0.143, p=0.009) and total cholesterol (r=−0.223,
p<0.001). Plasma ANGPTL4 did not correlate with age
(p=0.457), triglycerides (p=0.055) or FFA (p=0.226).
Plasma ANGPTL4 showed a positive correlation with
CRP (r=0.295, p<0.001; ﬁgure 2). Multiple regression
analysis revealed that the association between ANGPTL4
and CRP was independent of age, waist circumference,
glucose, HDL-cholesterol, triglycerides, total cholesterol,
FFA, and smoking (β=0.142, p=0.010).
Inflammation-dependent ANGPTL4 expression in human
macrophages
Since the above described correlations do not necessar-
ily implicate causal relationships, we performed mechan-
istic studies in vitro to get more insight into potential
causality between inﬂammation and ANGPTL4 expres-
sion. To demonstrate that ANGPTL4 expression is sensi-
tive to stimulation by inﬂammatory stimuli, we treated
macrophages with various PRR agonists and determined
ANGPTL4 expression (ﬁgure 3). We used human THP-1
macrophages because: (1) they are human macro-
phages, (2) they secrete sufﬁcient amounts of ANGPTL4
to allow quantiﬁcation in the cell medium.
In human THP-1 macrophages ANGPTL4 mRNA
expression (ﬁgure 3A) and ANGPTL4 protein secretion
(ﬁgure 3B) were strongly increased by the TLR4 agonist
LPS and the TLR3 agonist poly(I:C). Consistent with
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Figure 1 Plasma angiopoietin-like protein 4 (ANGPTL4)
in healthy controls (Controls), patients with metabolic
syndrome without (MetS−I) and with low-grade inflammation
(MetS+I) and patients with type 2 diabetes mellitus (T2DM).
Plasma was taken from Controls, patients with MetS−I, MetS
+I and T2DM, and plasma ANGPTL4 levels were determined.
As compared with plasma ANGPTL4 levels (median (IQR))
in Controls (3.7 (2.8–5.2) ng/mL), ANGPTL4 levels are
increased in patients with MetS−I (4.6 (3.3–6.5) ng/mL,
p=0.006), patients with MetS+I (6.0 (3.8–7.7) ng/mL, p<0.001)
and patients with T2DM (6.4 (5.2–8.2) ng/mL, p<0.001).
Furthermore, ANGPTL4 was increased in T2DM compared
with MetS−I (p<0.001). Significant as compared with
Controls. *p<0.001, #p<0.05.
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these data, LPS also increased ANGPTL4 mRNA expres-
sion in human U937 macrophages and human
monocyte-derived macrophages (ﬁgure 3C). Intralipid,
a source of FFA that induces foam cell formation, also
increased ANGPTL4 mRNA (ﬁgure 3D) and ANGPTL4
protein (ﬁgure 3E) expression in THP-1 macrophages,
but no clear synergy was observed between Intralipid
and LPS towards induction of ANGPTL4. Taken
together, these data show that inﬂammatory stimuli
causing macrophage activation and macrophage foam
cell formation markedly increase ANGPTL4 expression
in human macrophages.
DISCUSSION
The main ﬁndings of our cross-sectional human study
are: (1) patients with MetS and T2DM show increased
plasma ANGPTL4 levels compared with Controls, (2)
patients with MetS+I show higher levels of ANGPTL4
compared with patients with MetS−I, (3) plasma CRP, as
a marker of low-grade inﬂammation, positively correlates
with plasma ANGPTL4, independent of age, waist cir-
cumference, glucose and lipid variables.
Thus far, the expression of ANGPTL4 in numerous
tissues including adipose tissue and liver was thought to be
mainly regulated by PPARs. Consistent with a role of
PPARs, fatty acids increase ANGPTL4 expression in vitro
in numerous cell types.1 6–8 Furthermore, in vivo modula-
tion of plasma FFA levels also modulates plasma
ANGPTL4 levels,9 10 with a positive correlation observed
between the change in FFA levels and change in
ANGPTL4 levels.10 In our previous study, we postulated
that patients with T2DM may have higher ANGPTL4 levels
than healthy participants due to elevated plasma FFA.10
Although in the present paper we do observe increased
plasma ANGPTL4 levels in patients with T2DM compared
with Controls, plasma FFA levels were not different
between both groups. In addition, plasma ANGPTL4
levels were elevated in patients with MetS compared with
Controls, whereas their plasma FFA levels did not differ
from the healthy Controls. In fact, in this cross-sectional
study we were unable to detect a correlation between
plasma FFA levels and plasma ANGPTL4 levels, which is
likely related to the matching on visceral obesity and the
subsequent limited variation in FFA between groups.
Therefore, we hypothesized that additional factors
such as inﬂammation may contribute to the increased
ANGPTL4 levels in patients with MetS and T2DM.
Indeed, we did observe a progressive increase in the
plasma ANGPTL4 in males according to inﬂammatory
status (healthy Controls < patients with MetS−I < patients
with MetS+I and patients with T2DM). Furthermore, in
all groups combined, plasma ANGPTL4 showed a
positive correlation with CRP, an established marker for
low-grade inﬂammation.
To get more insight into the causal relationship
between inﬂammation and ANGPTL4 expression we
treated human macrophages with various PRR ligands.
Macrophages were used because of their sensitivity to
inﬂammatory stimuli, not because they are suspected to
be solely responsible for the changes in plasma
ANGPTL4 levels observed in vivo. Of all ligands tested,
agonists for TLR3 (ie, poly(I:C)) and TLR4 (ie, LPS)
consistently induced the expression and release of
ANGPTL4 in different types of human macrophages. It
remains unclear which intracellular pathway activated by
TLR activation is responsible for induction of ANGPTL4.
Also, it is unsure whether FFA, known to activate PRRs
such as TLR4 in adipocytes and macrophages,11 12 may
increase ANGPTL4 expression via TLR4 activation. It
should be noted that the similarity in plasma FFA levels
between the various groups despite major differences in
plasma ANGPTL4 levels, suggests that plasma FFA are
not a major determinant of ANGPTL4 in the population
studied. Since CRP itself is a marker rather than a medi-
ator of inﬂammation,18 the nature of the inﬂammatory
stimuli that cause an increase in plasma ANGPTL4 in
humans evidently still has to be identiﬁed. Also, it would
be of interest to study the response of ANGPTL4 to
inﬂammatory stimuli in other cell types, including
human adipocytes.
We hypothesized that the inﬂammation induced
increase in plasma ANGPTL4 in patient with MetS and
T2DM may induce further dyslipidemia. Indeed, taken
all groups together, we observed a modest negative cor-
relation between ANGPTL4 and plasma
HDL-cholesterol (r=−0.143; p<0.009). Some limitations
do apply to our study. First of all, we previously showed
that the ANGPTL4 ELISA measures full-length
ANGPTL4 and the C-terminal truncated fragment of
ANGPTL4 but not the N-terminal truncated fragment.
Only full-length and the N-terminal fragment of
ANGPTL4 inﬂuence plasma lipids. It is unclear to what
Figure 2 Correlation between plasma C reactive protein
(CRP) and angiopoietin-like protein 4 (ANGPTL4). Plasma
was taken from healthy controls, patients with metabolic
syndrome without and with low-grade inflammation and
patients with type 2 diabetes mellitus, and plasma ANGPTL4
levels as well as CRP levels were determined. Plasma CRP
correlates positively with plasma ANGPTL4 (r=0.295,
p<0.001).
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extent the plasma concentrations of C-terminal and full-
length ANGPTL4 reﬂect the concentration of
N-terminal ANGPTL4. The mechanism underlying the
relationship between inﬂammation and plasma
ANGPTL4 levels is unknown as yet, and probably
involves causal stimuli other than CRP that merely repre-
sents a marker of inﬂammation. Further studies into the
causal relationships are thus required. Also, it is unclear
why CRP is lower in T2DM compared with patients with
MetS+I. It should be noted that patients with well-
controlled diabetes with an HbA1c between 6.5% and
8.5%, a BMI between 25–32 kg/m2, BP <150/85 mm Hg,
and no history of diabetes-related complications were
included, who were treated with drugs such as statins
with pleotropic anti-inﬂammatory effects. Furthermore,
higher CRP in patients with MetS+I may be explained by
a higher percentage of smokers in that group. Also,
from the current study set up it is unclear whether the
relationship between ANGPTL4 and CRP in humans is
solely explained by activation of macrophages. Other
cell types and tissues may also be involved.
In conclusion, we provide a novel link between inﬂam-
mation and ANGPTL4. An increased inﬂammatory state in
patients with MetS and T2DM was associated with higher
plasma ANGPTL4 levels. Additionally, a positive correlation
was observed between plasma CRP and ANGPTL4.
Although in vitro studies conﬁrmed that PRR ligands
increase ANGPTL4 expression, further studies into the
precise mechanisms underlying the relationship between
inﬂammation and ANGPTL4 in humans are warranted.
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